Stay updated with breaking news from Abivax. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LONDON, Sept. 2, 2022 /PRNewswire/ -- Dechert advised Abivax on its successful €49.2 million financing with top U.S. and European biotech specialist investors. The financing was underwritten
PARIS, FRANCE / ACCESSWIRE / August 16, 2022 / Abivax SA (Euronext Paris:FR0012333284 - ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system
10.06.2022 - DGAP-News: ABIVAX / Key word(s): Miscellaneous Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting 10.06.2022 / 18:00 The issuer is solely responsible for the content of this announcement. Abivax ...
Phase 2a safety and efficacy study results of obefazimod (ABX464) in patients with rheumatoid arthritis (RA) published in the renowned and peer-reviewed journal "Annals of the Rheumatic Diseases (ARD)"
DGAP-News: ABIVAX / Key word: AGM/EGM ABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents... | May 18, 2022